- Home
- TRNS vs GYRE Comparison
TRNS vs GYRE Comparison
Compare TRNS & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRNS
- GYRE
- Stock Information
- Founded
- TRNS 1964
- GYRE 2002
- Country
- TRNS United States
- GYRE United States
- Employees
- TRNS N/A
- GYRE N/A
- Industry
- TRNS Electrical Products
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- TRNS Industrials
- GYRE Health Care
- Exchange
- TRNS Nasdaq
- GYRE Nasdaq
- Market Cap
- TRNS 748.7M
- GYRE 897.1M
- IPO Year
- TRNS N/A
- GYRE N/A
- Fundamental
- Price
- TRNS $87.38
- GYRE $9.07
- Analyst Decision
- TRNS Buy
- GYRE
- Analyst Count
- TRNS 4
- GYRE 0
- Target Price
- TRNS $108.67
- GYRE N/A
- AVG Volume (30 Days)
- TRNS 139.6K
- GYRE 337.8K
- Earning Date
- TRNS 05-19-2025
- GYRE 05-09-2025
- Dividend Yield
- TRNS N/A
- GYRE N/A
- EPS Growth
- TRNS N/A
- GYRE N/A
- EPS
- TRNS 1.57
- GYRE 0.02
- Revenue
- TRNS $278,421,000.00
- GYRE $100,643,000.00
- Revenue This Year
- TRNS $11.73
- GYRE $22.01
- Revenue Next Year
- TRNS $5.05
- GYRE $88.14
- P/E Ratio
- TRNS $55.66
- GYRE $112.98
- Revenue Growth
- TRNS 7.30
- GYRE N/A
- 52 Week Low
- TRNS $67.56
- GYRE $6.11
- 52 Week High
- TRNS $147.12
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- TRNS 55.43
- GYRE 45.78
- Support Level
- TRNS $88.46
- GYRE $9.26
- Resistance Level
- TRNS $93.77
- GYRE $11.61
- Average True Range (ATR)
- TRNS 4.00
- GYRE 1.09
- MACD
- TRNS 0.33
- GYRE -0.21
- Stochastic Oscillator
- TRNS 47.96
- GYRE 28.12
About TRNS Transcat Inc.
Transcat Inc is involved in providing calibration and laboratory instrument services and distribution of test, measurement, and control instrumentation. Its product and services portfolio consists of calibration instruments, dimensional measuring tools, Electrical test instruments, pressure measurement, etc. The firm has Service and Distribution operating segments. It derives the majority of its revenues from the Service segment. The firm promotes and sells its products under brand names such as Estech, FLIR, Fluke, Keysight, and Megger among others. It serves to pharmaceutical, industrial manufacturing, energy, and chemical process industries.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.